Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Multicenter open-label sertraline study in adolescent outpatients with major depression
Autore:
Ambrosini, PJ; Wagner, KD; Biederman, J; Glick, I; Tan, C; Elia, J; Hebeler, JR; Rabinovich, H; Lock, J; Geller, D;
Indirizzi:
MedAColl Penn & Hahnemann Univ, Eastern Penn Psychiat Inst, Philadelphia, P Med Coll Penn & Hahnemann Univ Philadelphia PA USA 19129 Philadelphia, P Univ Texas, Med Branch, Galveston, TX 77550 USA Univ Texas Galveston TX USA 77550 as, Med Branch, Galveston, TX 77550 USA Harvard Univ, Sch Med, Boston, MA USA Harvard Univ Boston MA USAHarvard Univ, Sch Med, Boston, MA USA Stanford Univ, Sch Med, Stanford, CA 94305 USA Stanford Univ Stanford CA USA 94305 Univ, Sch Med, Stanford, CA 94305 USA Pfizer Inc, New York, NY USA Pfizer Inc New York NY USAPfizer Inc, New York, NY USA Univ Penn, Philadelphia, PA 19104 USA Univ Penn Philadelphia PA USA 19104Univ Penn, Philadelphia, PA 19104 USA Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA Thomas Jefferson Univ Philadelphia PA USA 19107 hiladelphia, PA 19107 USA
Titolo Testata:
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
fascicolo: 5, volume: 38, anno: 1999,
pagine: 566 - 572
SICI:
0890-8567(199905)38:5<566:MOSSIA>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
OBSESSIVE-COMPULSIVE DISORDER; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; CHILDREN; NORTRIPTYLINE; FLUOXETINE; SCALE;
Keywords:
adolescent; depression; sertraline; pharmacotherapy; rating scales;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Citazioni:
19
Recensione:
Indirizzi per estratti:
Indirizzo: Ambrosini, PJ Med Coll Penn & Hahnemann Univ, Eastern Penn Psychiat Inst, 3200 Henry Ave, Med Coll Penn & Hahnemann Univ 3200 Henry Ave Philadelphia PA USA 19129
Citazione:
P.J. Ambrosini et al., "Multicenter open-label sertraline study in adolescent outpatients with major depression", J AM A CHIL, 38(5), 1999, pp. 566-572

Abstract

Objective: The aim of this multicenter outpatient study was to assess the therapeutic benefits, response patterns, and safety of sertraline in adolescent major depressive disorder (MDD). Method: Fifty-three adolescent outpatients with MDD were treated in an open-label, 10-week, acute-phase trial with sertraline and, if responders, for an additional 12-week continuation phase. Diagnostic and response assessments included the Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS), 17-item K-SADS-derived depression severity score, Hamilton Depression Rating Scale, Beck Depression Inventory, and Clinical Global Impression Scale. Results: By 2 weeks, when analyzed as continuous variables, all severity scores showed significant differences from baseline. This pattern persisted through 10 weeks, with a significantly greater response occurring when treatment was extended from 6 to 10 weeks. Both clinician- and patient-rated improvement wasmaintained during continuation treatment. Response rates varied considerably when depression rating scales were analyzed categorically. Sertraline was generally well tolerated and did not induce manic symptoms. Conclusions: In open treatment of adolescent MDD with sertraline, significant improvement occurred early on and was maintained for 22 weeks. Absolute response rates varied depending on the rating scales used, definition of response, and length of treatment. Maximal response rates were obtained by clinician-defined ratings after 10 weeks of treatment.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 19:30:02